LYSET/TMEM251- a novel key component of the mannose 6-phosphate pathway.


Journal

Autophagy
ISSN: 1554-8635
Titre abrégé: Autophagy
Pays: United States
ID NLM: 101265188

Informations de publication

Date de publication:
07 2023
Historique:
pmc-release: 22 01 2024
medline: 22 6 2023
pubmed: 13 1 2023
entrez: 12 1 2023
Statut: ppublish

Résumé

Degradation of macromolecules delivered to lysosomes by processes such as autophagy or endocytosis is crucial for cellular function. Lysosomes require more than 60 soluble hydrolases in order to catabolize such macromolecules. These soluble hydrolases are tagged with mannose6-phosphate (M6P) moieties in sequential reactions by the Golgi-resident GlcNAc-1-phosphotransferase complex and NAGPA/UCE/uncovering enzyme (N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase), which allows their delivery to endosomal/lysosomal compartments through trafficking mediated by cation-dependent and -independent mannose 6-phosphate receptors (MPRs). We and others recently identified TMEM251 as a novel regulator of the M6P pathway via independent genome-wide genetic screening strategies. We renamed TMEM251 to LYSET (lysosomal enzyme trafficking factor) to establish nomenclature reflective to this gene's function. LYSET is a Golgi-localized transmembrane protein important for the retention of the GlcNAc-1-phosphotransferase complex in the Golgi-apparatus. The current understanding of LYSET's importance regarding human biology is 3-fold: 1) highly pathogenic viruses that depend on lysosomal hydrolase activity require LYSET for infection. 2) The presence of LYSET is critical for cancer cell proliferation in nutrient-deprived environments in which extracellular proteins must be catabolized. 3) Inherited pathogenic alleles of LYSET can cause a severe inherited disease which resembles GlcNAc-1-phosphotransferase deficiency (i.e., mucolipidosis type II).

Identifiants

pubmed: 36633450
doi: 10.1080/15548627.2023.2167376
pmc: PMC10283412
doi:

Substances chimiques

Mannose PHA4727WTP
mannose-6-phosphate 3672-15-9
Hydrolases EC 3.-
Receptor, IGF Type 2 0
Cations 0
Phosphotransferases EC 2.7.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2143-2145

Références

Science. 2022 Oct 7;378(6615):eabn5648
pubmed: 36074821
J Cell Sci. 2019 Jan 16;132(2):
pubmed: 30651381
Hum Mutat. 2021 Jan;42(1):89-101
pubmed: 33252156
Nat Commun. 2022 Sep 12;13(1):5351
pubmed: 36096887
Science. 2022 Oct 7;378(6615):eabn5637
pubmed: 36074822
Nat Med. 2005 Oct;11(10):1109-12
pubmed: 16200072
J Biol Chem. 2002 Jul 5;277(27):24609-17
pubmed: 11986312

Auteurs

Wenjie Qiao (W)

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Christopher M Richards (CM)

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Sabrina Jabs (S)

Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH